Cellectis appoints new CMO

In her new role, Brownstein will oversee clinical research and development for Cellectis UCART clinical trial programmes. She joins from Celgene, where she served as Vice President, Global Clinical Research and Development, Therapeutic Area Head for myeloid diseases. Previously, Brownstein served at Regeneron Pharmaceuticals where she led teams investigating multiple early development programmes and assets, including T-cell engaging bispecific antibodies. She started her career at Hoffman-La Roche (Roche Pharmaceuticals). Prior to that, she practiced as a paediatric oncologist amongst other in the New York Presbyterian Columbia University and Mount Sinai Medical Center.

Brownstein will be based in the Cellectis’ New York office and she is joining the executive committee.